Alcami Expands US API Capacity

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
Volume 11
Issue 9

CDMO Alcami adds HPAPI capacity and cryogenic capabilities to its Wisconsin facility.

CDMO Alcami, formed earlier in 2016 through a combination of AAIPharma Services and Cambridge Major Laboratories, plans to expand capabilities for development and manufacturing of APIs at its Germantown, WI facility, the company announced on Aug. 11, 2016.  The company plans to enhance new and existing kilo labs to introduce the development and manufacturing of highly potent APIs (HPAPIs).

Two new cGMP HPAPI production suites will focus on primary containment technologies with engineering controls designed to meet the established Occupational Exposure Limit (OEL) of minimally 0.03 μg/m3 (i.e., SafeBridge Category 3). The 5000-ft2 renovation will be operational by the first quarter of 2017. The newly designed space will include reactors of up to 150-L scale and cryogenic capabilities to service a wide range of complex chemistries.

These advancements follow operational and technology enhancements across development, clinical, and commercial manufacturing to increase production capacity by 50%. This positions Alcami’s global API operations (Germantown, WI and Weert, The Netherlands) to meet the increasing demand of new clinical candidates, of which greater than 70% originate from small and mid-size pharma and biotech. The Germantown, WI facility recently completed an FDA General Inspection that resulted in zero 483 observations, the company notes.

Source: Alcami

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content